Optimizing HER2 Positive Early Breast Cancer Management – Saskatchewan


  • To review updated evidence as it relates to early-stage/curative HER-2 positive breast cancer assessment and treatment
  • To integrate evidence and consensus into practical approaches for the management of HER-2 positive early breast cancer
  • Focus on the paradigm shift of treating HER2 positive breast cancer in the neoadjuvant setting, discuss escalation versus de-escalation of therapies



Thursday, December 02, 2021


5:00 pm - 6:00 pm


Registration is complimentary and restricted to healthcare professionals. Please click the button below to complete the transaction:

personAbout the Faculty

Dr. Osama Ahmed

Dr. Osama Ahmed


Dr. Osama Ahmed is a Medical Oncologist at the Saskatoon Cancer Centre and an Assistant Professor in the College of Medicine at the University of Saskatchewan. He obtained his medical school training at the University of Alexandria, Egypt and performed his Internal Medicine residency at the University of Saskatchewan in Saskatoon.Dr. Ahmed completed his Medical Oncology training at the University of Calgary. He is a fellow of the Royal College of Physicians and Surgeons of Canada. His areas of interest are Breast malignancies, Sarcoma, Neuro-oncology and Gastrointestinal oncology. In addition to patients care he is committed to medical education and research. He is an active member of Canadian clinical trials Group (CCTG)and Canadian Association of Medical Oncologists (CAMO). He’s currently the Provincial Disease Site Group Chair for Breast Malignancies in Saskatchewan.

Joyce A. O’Shaughnessy

Dr. Joyce O’Shaughnessy


Joyce A. O’Shaughnessy, M.D. specializes in medical oncology with board certification in both internal medicine as well as medical oncology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certification in medical oncology. Dr. O’Shaughnessy focuses on her practice and clinical research on breast cancer treatment. She is Directorof Breast Cancer Research and at Baylor-Sammons Cancer Center and Chair of Breast Cancer Research for US Oncology


This program has been made possible through unrestricted support from Knight Therapeutics.